PL2001456T3 - Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych - Google Patents

Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych

Info

Publication number
PL2001456T3
PL2001456T3 PL07727719T PL07727719T PL2001456T3 PL 2001456 T3 PL2001456 T3 PL 2001456T3 PL 07727719 T PL07727719 T PL 07727719T PL 07727719 T PL07727719 T PL 07727719T PL 2001456 T3 PL2001456 T3 PL 2001456T3
Authority
PL
Poland
Prior art keywords
treatment
opioid receptor
receptor antagonist
kappa opioid
containing compositions
Prior art date
Application number
PL07727719T
Other languages
English (en)
Polish (pl)
Inventor
Lars-Holger Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of PL2001456T3 publication Critical patent/PL2001456T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL07727719T 2006-04-04 2007-04-03 Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych PL2001456T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
EP07727719A EP2001456B1 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
PL2001456T3 true PL2001456T3 (pl) 2010-05-31

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07727719T PL2001456T3 (pl) 2006-04-04 2007-04-03 Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych

Country Status (17)

Country Link
US (1) US8063059B2 (OSRAM)
EP (1) EP2001456B1 (OSRAM)
JP (1) JP5128578B2 (OSRAM)
AT (1) ATE450256T1 (OSRAM)
AU (1) AU2007236003B2 (OSRAM)
CA (1) CA2646899C (OSRAM)
CY (1) CY1109862T1 (OSRAM)
DE (1) DE502007002185D1 (OSRAM)
DK (1) DK2001456T3 (OSRAM)
EA (1) EA014820B1 (OSRAM)
ES (1) ES2337622T3 (OSRAM)
HR (1) HRP20100113T1 (OSRAM)
PL (1) PL2001456T3 (OSRAM)
PT (1) PT2001456E (OSRAM)
RS (1) RS51211B (OSRAM)
SI (1) SI2001456T1 (OSRAM)
WO (1) WO2007115975A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101925576B (zh) 2008-01-22 2013-02-06 伊莱利利公司 κ-选择性阿片受体拮抗剂
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
JP6448645B2 (ja) * 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
PT3137081T (pt) 2014-04-28 2018-02-08 Orphomed Inc Dímero de buprenorfina e o seu uso no tratamento de transtornos gastrointestinais
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
JP2025508051A (ja) 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ，インコーポレーテッド 大うつ病性障害の治療に使用するためのアチカプラントの多形形態

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1365756A2 (en) * 2000-08-15 2003-12-03 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6528518B2 (en) 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1613617A4 (en) * 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
JP2007526328A (ja) 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
EP1750675B1 (en) * 2004-06-02 2008-10-29 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and salt thereof

Also Published As

Publication number Publication date
AU2007236003B2 (en) 2012-10-18
CY1109862T1 (el) 2014-09-10
US8063059B2 (en) 2011-11-22
EA200802104A1 (ru) 2009-04-28
ES2337622T3 (es) 2010-04-27
PT2001456E (pt) 2010-03-03
DK2001456T3 (da) 2010-04-12
WO2007115975A3 (de) 2008-02-14
SI2001456T1 (sl) 2010-04-30
AU2007236003A1 (en) 2007-10-18
EP2001456A2 (de) 2008-12-17
WO2007115975A2 (de) 2007-10-18
CA2646899A1 (en) 2007-10-18
EA014820B1 (ru) 2011-02-28
ATE450256T1 (de) 2009-12-15
CA2646899C (en) 2014-05-06
JP2009532434A (ja) 2009-09-10
HRP20100113T1 (hr) 2010-04-30
US20090181999A1 (en) 2009-07-16
EP2001456B1 (de) 2009-12-02
JP5128578B2 (ja) 2013-01-23
DE502007002185D1 (de) 2010-01-14
RS51211B (sr) 2010-12-31

Similar Documents

Publication Publication Date Title
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
NZ594140A (en) C5ar antagonists
SI2001456T1 (sl) Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
IL201790A0 (en) Pyridyl piperidine orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
ZA200710611B (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
SI2049529T1 (sl) Substituiran diazepan oreksin receptor antagonist
SI1729753T1 (sl) Uporaba antagonistov NMDA receptorjev za zdravljenje tinitusa povzročenega s kohlearno eksitotoksičnostjo
PT2001876E (pt) Compostos de 8-azabiciclo[3.2.1]octano como antagonistas do receptor opióide mu
MX2009004662A (es) Compuestos de pirazolina como antagonistas receptores de mineralocorticoides.
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
PL2238110T3 (pl) Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EP2075252A4 (en) NK1 Receptor Antagonists COMPOSITION
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
ZA200607159B (en) Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ZA200900613B (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders
ZA200705524B (en) Synthesis of CCR5 receptor antagonists
MX2009006313A (es) Antagonistas v3 para el tratamiento o prevencion de dolor cronico.
HK1127349A (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders
HK1155643A (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
ZA200906849B (en) Mineralcorticoid receptor antagonists for the treatment of endomertriosis
HK1143399A (en) Methods for inhibiting angiogenesis using egfl8 antagonists